The company will use a portion of the credit facility to fund its announced acquisition of Integrated DNA Technologies.
The company entered an agreement with JP Morgan Chase that provides a five-year unsecured $300 million term loan and a $1.5 billion revolving facility.
The company immediately borrowed $255 million to pay part of the $680 million price tag for Alere's MeterPro cardiovascular and toxicology business and its BNP assay business.
The firm said that it expects to use the proceeds of the senior notes offering to contribute to retirement of remaining convertible notes.
Castle will use the proceeds to accelerate marketing and new product development related to its molecular prognostic tests for patients with underserved cancers.
The infectious disease diagnostics firm will initially receive $40 million from CRG, most of which will go towards paying down existing debt.
The company borrowed $205 million in revolving loans from the credit facility, which matures on December 23, 2021.
The company said it will use the proceeds for various purposes, including working capital, capital expenditures, stock repurchases, dividends, and acquisitions.
The company took out the credit in connection with its $4.2 billion pending acquisition of electron microscopy firm FEI.
The firm did not disclose how it intended to use the $8 million, but said that it would provide temporary working capital.
A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.
Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.
In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.
A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.